Last reviewed · How we verify
NCT00018863
Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)
Phase 3 trial testing Methylphenidate in Attention Deficit Disorder With Hyperactivity in 165 participants. Completed in 30 November 2006.
31 March 2006
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 165 |
| Start date | 1 April 2001 |
| Primary completion | 31 March 2006 |
| Estimated completion | 30 November 2006 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Methylphenidate (methylphenidate) — full drug profile →
Conditions studied
- Attention Deficit Disorder With Hyperactivity — all drugs for Attention Deficit Disorder With Hyperactivity →
Sponsor
New York State Psychiatric Institute
Who can join
Adults 3 to 5, any sex, with Attention Deficit Disorder With Hyperactivity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00018863
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Methylphenidate
Trials testing the same drug.
- NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
- NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
- NCT06580041 — Precision Care for Major Depressive Disorder · Phase 4 · enrolling by invitation
- NCT06355414 — Psilocybin in Chronic Low Back Pain and Depression · Phase 1 · recruiting
- NCT05776056 — Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints · Phase 4 · recruiting
Other recruiting trials for Attention Deficit Disorder With Hyperactivity
Currently open trials in the same condition.
- NCT06974136 — tES Modalities for the Treatment of ADHD · NA · recruiting
- NCT06764810 — Association Between Motor Skills and Sensory Profiles in Children With Typical and Atypical Development Aged 4 to 11 Yea · recruiting
- NCT05621174 — The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD · NA · active not recruiting
- NCT06369714 — Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. · NA · recruiting
- NCT00001246 — Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers · active not recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00018863 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 2 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00018863.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing